Literature DB >> 34362021

Benefits of Steroid Therapy in COVID-19 Patients with Different PaO2/FiO2 Ratio at Admission.

Serena Vita1, Daniele Centanni1, Simone Lanini1, Pierluca Piselli1, Silvia Rosati1, Maria Letizia Giancola1, Annalisa Mondi1, Carmela Pinnetti1, Simone Topino1, Pierangelo Chinello1, Silvia Mosti1, Gina Gualano1, Francesca Faraglia1, Fabio Iacomi1, Luisa Marchioni1, Micaela Maritti1, Enrico Girardi1, Giuseppe Ippolito1, Emanuele Nicastri1.   

Abstract

INTRODUCTION: The use of steroid therapy in patients within the context of SARS-CoV-2 infection is still a matter of debate. This study aimed to evaluate if potential steroid benefits could be predicted by the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2) (P/F) in COVID-19 patients at admission.
MATERIALS AND METHODS: Medical records were retrospectively collected from all adult patients admitted because of COVID-19 from 29 January to 31 July 2020. The association of steroid therapy with 28-day all-cause mortality outcome was analysed in a multivariable logistic regression model adjusted for confounding factors.
RESULTS: Overall, 511 patients were analysed, of which 39.1% underwent steroid therapy. Steroid treated patients were mostly male, older, and more frequently treated with antiviral drugs and aminoquinolines; the most common comorbidities were hypertension, followed by cardiovascular disease. Overall, 51 patients died within 28-days, and overall 28-days mortality was 19.5% in the cohort of patients exposed to steroids versus 3.9% mortality in unexposed patients (p < 0.001). Steroid therapy on patients with P/F ratio of 235 mmHg or higher at admission can be considered as detrimental, with an 8% increased probability of death.
CONCLUSIONS: Steroid therapy is associated with increased 28-day mortality in COVID-19 in patients with mild or no ARDS.

Entities:  

Keywords:  ARDS; COVID-19; Sars-CoV-2 pneumonia; steroids

Year:  2021        PMID: 34362021     DOI: 10.3390/jcm10153236

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  2 in total

1.  A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study.

Authors:  Janwillem Kocks; Marjan Kerkhof; Jan Scherpenisse; Aimée van de Maat; Iris van Geer-Postmus; Thomas le Rütte; Jan Schaart; Reinold O B Gans; Huib A M Kerstjens
Journal:  ERJ Open Res       Date:  2022-05-30

2.  Clinical Characteristics of COVID-19: Use of Steroids in Mostly Unvaccinated COVID-19 Patients Before the Omicron Variant.

Authors:  Sang-Min Oh; Sin Young Ham; Hyeon Jeong Suh; Eunyoung Lee; Sang-Won Park
Journal:  J Korean Med Sci       Date:  2022-07-25       Impact factor: 5.354

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.